The efficacy of radiotherapy in association with multidisciplinary treatment for portal tumor emboli of hepatocellular carcinoma

Kengo Himei, Michinori Yamamoto, Kuniaki Katsui, Atsushi Yoshida, Mitsuhiro Takemoto, Mitsuru Kobayashi, Masahiro Kuroda, Katsuyoshi Sakae, Susumu Kanazawa, Yoshio Hiraki

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate the efficacy of radiotherapy for portal tumor emboli of hepatocellular carcinoma. Materials and Methods: Twenty-four patients with portal tumor emboli of hepatocellular carcinoma who were treated with radiotherapy from August 1995 to December 1999 were retrospectively studied. Patients were classified according to the degree of portal tumor emboli (Vp2: 3. Vp3: 14. Vp4: 7) and liver damage (A: 8, B: 11, C: 4. unknown: 1). The responses were classified as effective, no change, or progression. The liver function between pre- and post-radiotherapy was compared. Results: The responses were effective for 12 cases (75%) and no change for 4 cases (25%). Cause specific survival rate at 1 year and 50% survival time was 24.4% and 6.3 months, respectively. Cause specific survival rate at 1 year for liver damage A and Vp3 were 60% and 38% respectively. 50% survival time for liver damage A and Vp3 were 11 months and 11.3 months respectively. Prolongation of the prognosis over 6 months was observed in a few cases of liver damage B. Liver function with local irradiation was generally tolerable. Conclusions: Radiotherapy for portal tumor emboli of hepatocellular carcinoma was useful as one of multimodality treatments for advanced hepatocellular carcinoma. This treatment sometimes expected prolongation of the prognosis for hepatocellular carcinoma with portal tumor emboli.

Original languageEnglish
Pages (from-to)33-38
Number of pages6
JournalJournal of JASTRO
Volume14
Issue number1
DOIs
Publication statusPublished - 2002

Fingerprint

Embolism
Hepatocellular Carcinoma
Radiotherapy
Liver
Neoplasms
Therapeutics
Survival Rate
Survival

Keywords

  • Hepatocellular carcinoma
  • Portal tumor emboli
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

The efficacy of radiotherapy in association with multidisciplinary treatment for portal tumor emboli of hepatocellular carcinoma. / Himei, Kengo; Yamamoto, Michinori; Katsui, Kuniaki; Yoshida, Atsushi; Takemoto, Mitsuhiro; Kobayashi, Mitsuru; Kuroda, Masahiro; Sakae, Katsuyoshi; Kanazawa, Susumu; Hiraki, Yoshio.

In: Journal of JASTRO, Vol. 14, No. 1, 2002, p. 33-38.

Research output: Contribution to journalArticle

Himei, Kengo ; Yamamoto, Michinori ; Katsui, Kuniaki ; Yoshida, Atsushi ; Takemoto, Mitsuhiro ; Kobayashi, Mitsuru ; Kuroda, Masahiro ; Sakae, Katsuyoshi ; Kanazawa, Susumu ; Hiraki, Yoshio. / The efficacy of radiotherapy in association with multidisciplinary treatment for portal tumor emboli of hepatocellular carcinoma. In: Journal of JASTRO. 2002 ; Vol. 14, No. 1. pp. 33-38.
@article{f324e3faea9846d9a1be5e8427adc622,
title = "The efficacy of radiotherapy in association with multidisciplinary treatment for portal tumor emboli of hepatocellular carcinoma",
abstract = "Purpose: To evaluate the efficacy of radiotherapy for portal tumor emboli of hepatocellular carcinoma. Materials and Methods: Twenty-four patients with portal tumor emboli of hepatocellular carcinoma who were treated with radiotherapy from August 1995 to December 1999 were retrospectively studied. Patients were classified according to the degree of portal tumor emboli (Vp2: 3. Vp3: 14. Vp4: 7) and liver damage (A: 8, B: 11, C: 4. unknown: 1). The responses were classified as effective, no change, or progression. The liver function between pre- and post-radiotherapy was compared. Results: The responses were effective for 12 cases (75{\%}) and no change for 4 cases (25{\%}). Cause specific survival rate at 1 year and 50{\%} survival time was 24.4{\%} and 6.3 months, respectively. Cause specific survival rate at 1 year for liver damage A and Vp3 were 60{\%} and 38{\%} respectively. 50{\%} survival time for liver damage A and Vp3 were 11 months and 11.3 months respectively. Prolongation of the prognosis over 6 months was observed in a few cases of liver damage B. Liver function with local irradiation was generally tolerable. Conclusions: Radiotherapy for portal tumor emboli of hepatocellular carcinoma was useful as one of multimodality treatments for advanced hepatocellular carcinoma. This treatment sometimes expected prolongation of the prognosis for hepatocellular carcinoma with portal tumor emboli.",
keywords = "Hepatocellular carcinoma, Portal tumor emboli, Radiotherapy",
author = "Kengo Himei and Michinori Yamamoto and Kuniaki Katsui and Atsushi Yoshida and Mitsuhiro Takemoto and Mitsuru Kobayashi and Masahiro Kuroda and Katsuyoshi Sakae and Susumu Kanazawa and Yoshio Hiraki",
year = "2002",
doi = "10.11182/jastro1989.14.33",
language = "English",
volume = "14",
pages = "33--38",
journal = "Journal of JASTRO",
issn = "1040-9564",
publisher = "Editorial Board of JASTRO",
number = "1",

}

TY - JOUR

T1 - The efficacy of radiotherapy in association with multidisciplinary treatment for portal tumor emboli of hepatocellular carcinoma

AU - Himei, Kengo

AU - Yamamoto, Michinori

AU - Katsui, Kuniaki

AU - Yoshida, Atsushi

AU - Takemoto, Mitsuhiro

AU - Kobayashi, Mitsuru

AU - Kuroda, Masahiro

AU - Sakae, Katsuyoshi

AU - Kanazawa, Susumu

AU - Hiraki, Yoshio

PY - 2002

Y1 - 2002

N2 - Purpose: To evaluate the efficacy of radiotherapy for portal tumor emboli of hepatocellular carcinoma. Materials and Methods: Twenty-four patients with portal tumor emboli of hepatocellular carcinoma who were treated with radiotherapy from August 1995 to December 1999 were retrospectively studied. Patients were classified according to the degree of portal tumor emboli (Vp2: 3. Vp3: 14. Vp4: 7) and liver damage (A: 8, B: 11, C: 4. unknown: 1). The responses were classified as effective, no change, or progression. The liver function between pre- and post-radiotherapy was compared. Results: The responses were effective for 12 cases (75%) and no change for 4 cases (25%). Cause specific survival rate at 1 year and 50% survival time was 24.4% and 6.3 months, respectively. Cause specific survival rate at 1 year for liver damage A and Vp3 were 60% and 38% respectively. 50% survival time for liver damage A and Vp3 were 11 months and 11.3 months respectively. Prolongation of the prognosis over 6 months was observed in a few cases of liver damage B. Liver function with local irradiation was generally tolerable. Conclusions: Radiotherapy for portal tumor emboli of hepatocellular carcinoma was useful as one of multimodality treatments for advanced hepatocellular carcinoma. This treatment sometimes expected prolongation of the prognosis for hepatocellular carcinoma with portal tumor emboli.

AB - Purpose: To evaluate the efficacy of radiotherapy for portal tumor emboli of hepatocellular carcinoma. Materials and Methods: Twenty-four patients with portal tumor emboli of hepatocellular carcinoma who were treated with radiotherapy from August 1995 to December 1999 were retrospectively studied. Patients were classified according to the degree of portal tumor emboli (Vp2: 3. Vp3: 14. Vp4: 7) and liver damage (A: 8, B: 11, C: 4. unknown: 1). The responses were classified as effective, no change, or progression. The liver function between pre- and post-radiotherapy was compared. Results: The responses were effective for 12 cases (75%) and no change for 4 cases (25%). Cause specific survival rate at 1 year and 50% survival time was 24.4% and 6.3 months, respectively. Cause specific survival rate at 1 year for liver damage A and Vp3 were 60% and 38% respectively. 50% survival time for liver damage A and Vp3 were 11 months and 11.3 months respectively. Prolongation of the prognosis over 6 months was observed in a few cases of liver damage B. Liver function with local irradiation was generally tolerable. Conclusions: Radiotherapy for portal tumor emboli of hepatocellular carcinoma was useful as one of multimodality treatments for advanced hepatocellular carcinoma. This treatment sometimes expected prolongation of the prognosis for hepatocellular carcinoma with portal tumor emboli.

KW - Hepatocellular carcinoma

KW - Portal tumor emboli

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85024712734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024712734&partnerID=8YFLogxK

U2 - 10.11182/jastro1989.14.33

DO - 10.11182/jastro1989.14.33

M3 - Article

VL - 14

SP - 33

EP - 38

JO - Journal of JASTRO

JF - Journal of JASTRO

SN - 1040-9564

IS - 1

ER -